# **31st ECCV D Online** 9 – 12 July 2021 ESCMID EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES

#### INTRODUCTION

The recent and fast emergence of carbapenem-resistant Klebsiella pneumoniae strains calls for urgent development of alternatives to antibiotics. This major burden has been linked to the dissemination of few successful high-risk clones, such as the ST307 lineage which has spread in different parts of the world, and currently exhibits various carbapenemase-production patterns.

Bacteriophage therapy is a promising strategy to face multidrug resistance. Here, we report the description of the V1KP1 Jumbo phage and the evaluation of its activity against a panel of K. pneumoniae strains belonging to various ST including ST307 and producing various types of carbapenemases. We also assessed the impact of capsule type on V1KP1 activity as it has previously been associated to phage specificity.<sup>1</sup>

#### METHODS

#### Phages

V1KP1 was isolated from a sewage sample on a ST307 clinical strain. A: Phage morphology was characterized using transmission electronic microscopy (Jeol 1400 JEM, Tokyo, Japan).

**B**: Phage genome was sequenced using Illumina/Miseq technology and annotated using PATRIC (v 3.6.9)

C: Jumbo phage activity was evaluated through the spot test assay and the determination of the **Efficiency Of Plating** ratio (n=3):

> EOP = - phage titer on a test strain phage titer on a reference strain

**D**: Capsule type was determined using *wzi* gene sequencing<sup>1</sup> (Brisse *et al*, J. Clin. Microbiol. 2013, 51(12):4073).

#### Bacterial strains

The panel included 83 clinical strains of *K. pneumoniae* belonging to different strain types. ST307 was over-represented (n=30) on purpose to evaluate phage activity on this prevalent sequence type.

## **Isolation and characterization of a novel Jumbo phage active against** the emerging ST307 carbapenemase-producing K. pneumoniae clone

#### ARNAUD<sup>1,2</sup>, L. DORTET<sup>5</sup>, T. FERRY<sup>2,3,4</sup>, F. LAURENT<sup>1,2,3</sup>, on behalf of the PHAGE*in*Lyon study group.

Department of bacteriology, National Reference Centre for Staphylococci, Lyon University Hospital, France. 2. CIRI – Team "pathogenesis of staphylococcal infections, Lyon, France. 3. Regional Reference Centre for Bone and Joint Infections (CRIOAc), Lyon University hospital, France. 4. Department of infectious diseases, Lyon University Hospital, France 5. National Reference Centre for Antibiotics resistance, Bicêtre Hospital, France.

A-B TEM analysis of V1KP1. Phage suspension was studied and showed Myoviridae particles with an average diameter of 95 and 125 nm for the length of the phage capsid and the tail respectively (Fig 1). Phage V1KP1 possesses a 346 057 bp genome and thus belongs to a unique group of phages, known as Jumbo phages. Sequence analysis showed that it belonged to the *Myoviridae* family and the *Alcyoneusvirus* genus. V1KP1 best blast hit (NCBI) is vb\_KleM\_RaK2 (91% cov ; 98.46% id). We identified 626 predicted protein-coding genes, covering 94.5% of the genome (Fig 2).

Figure 2. V1KP1 annotation. Circular genomic map of V1KP1 genome

tRNA-Leu-TAA tRNA-Pseudo-GTG

tRNA-Ser-TGA Phage endonuclea

age HNH homing endonuclea

NA-Asn-GTT RNA-Ara-TCT V1KP1 morphology. **TEM observation** 

Figure 1.

Putative dCM **RnIA RNA ligase 1 and tail fib** idase PhoH-like prot/ utative nicotinate phosp anaerobic ribonucle Phage non-contractile tail outative tail fiber protein putative structural protei Thymidine kinase il sheath protein putative tail

hymidylate synthas

seplate hub structural protein / Phage lysozyme R DNA primase subun outative tail fiber protein

ortal vertex protei

**DNA** helicase

#### CONCLUSIONS

Phage V1KP1 genome analysis revealed a novel phage belonging to Alcyoneusvirus genus. The phage V1KP1 is active on a large panel of ST307 isolates, regardless of the type of carbapenemase produced. We noticed that it is active on several *K. pneumoniae* STs and this activity is not related to capsule types.

M. MEDINA<sup>1,2</sup>, <u>C. KOLENDA<sup>1,2,3</sup>, M. BONHOMME<sup>1,2</sup>, M. SERAIN<sup>1,2</sup>, T. LEGENDRE<sup>1,2</sup>, L. BLAZERE<sup>1,2</sup></u>,



### RESULTS

- > V1KP1 presented a narrow host range. It was active against 80% (24/30) of ST307 strains and 9,4% (5/53) of non-ST307 strains, including all ST16 (3/3) and ST20 (1/1), ST327 (1/1) isolates. Of note, it was not active against strains belonging to STs closely related to ST307.
- > V1KP1 activity on ST307 strains did not depend on carbapenemase production (Table 1).
- Capsular type was not predictive of phage activity. If wzi alleles were well conserved among ST307 strains (allele type 173), ST11, ST16 and ST45 shared the same capsule type but V1KP1 was active only against ST16 strains. V1KP1 was also active against 2 other strains (ST327, ST20) with distant allele types (Fig 3).

		Carbapenemase	V1KP1 activity
		None	1/1
		<b>OXA-48</b>	12/14
9 deaminase er attachment catalyst		OXA-181	2/2
n Phage pyruvate formate-lyase noribosyltransferase oside-triphosphate reductase l fiber protein Gp17		OXA-1, OXA-48	1/2
		NDM-1	1/2
		NDM-7	3/4
		KPC-3	4/4
n		VIM-1	0/1
tive tail fiber protein ative tail fiber protein il fiber protein	CDS	Table 1. Phage V1KP1 activity accordi to carbabenemase production of ST3	
	RNA		
	GC Content	strains.	
	GC Skew+	x/y: x=sensitive strai	ins; y=number
	GC Skew-	tested strains	



## PHAGEinLYON



**C** - **D** 

Tree scale: 0.01 🛏

0 STOO



Figure 3. Phage V1KP1 host range according to ST and *wzi* allele sequence.

Phylogenetic tree built based on *wzi* gene sequences.

First layer: green = ST307 strains; Black = others Middle layer: WZI allele type; ~ = closest wzi allele External layer: V1KP1 activity (blue square=EOP>0; empty=no or weak lysis)

### ACKNOWLEDGEMENTS

We thank the "Fondation HCL" for the financial support of this study.



### **CONTACT INFORMATION**

Mathieu MEDINA, Lyon University Hospital mathieu.medina@chu-lyon.fr